Neilsen PM - Search Results

1

Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells.

Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, Børresen-Dale AL, Neilsen PM, Prives C. Pfister NT, et al. Among authors: neilsen pm. Genes Dev. 2015 Jun 15;29(12):1298-315. doi: 10.1101/gad.263202.115. Epub 2015 Jun 16. Genes Dev. 2015. PMID: 26080815 Free PMC article.

2

Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

Shakya R, Tarulli GA, Sheng L, Lokman NA, Ricciardelli C, Pishas KI, Selinger CI, Kohonen-Corish MRJ, Cooper WA, Turner AG, Neilsen PM, Callen DF. Shakya R, et al. Among authors: neilsen pm. Oncogene. 2017 Aug;36(31):4469-4480. doi: 10.1038/onc.2017.66. Epub 2017 Apr 3. Oncogene. 2017. PMID: 28368395

3

p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNA.

Yu F, Bracken CP, Pillman KA, Lawrence DM, Goodall GJ, Callen DF, Neilsen PM. Yu F, et al. Among authors: neilsen pm. PLoS One. 2015 Jun 10;10(6):e0129190. doi: 10.1371/journal.pone.0129190. eCollection 2015. PLoS One. 2015. PMID: 26061048 Free PMC article.

4

Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells.

Kumar R, Selth LA, Schulz RB, Tay BS, Neilsen PM, Callen DF. Kumar R, et al. Among authors: neilsen pm. J Cell Biochem. 2011 Oct;112(10):2742-7. doi: 10.1002/jcb.23214. J Cell Biochem. 2011. PMID: 21678463

5

Identification of ANKRD11 as a p53 coactivator.

Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. Neilsen PM, et al. J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52. doi: 10.1242/jcs.026351. Epub 2008 Oct 7. J Cell Sci. 2008. PMID: 18840648

6

Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF. Neilsen PM, et al. Oncogene. 2013 Jun 13;32(24):2992-3000. doi: 10.1038/onc.2012.305. Epub 2012 Jul 16. Oncogene. 2013. PMID: 22797073

7

The oncogenic role of miR-155 in breast cancer.

Mattiske S, Suetani RJ, Neilsen PM, Callen DF. Mattiske S, et al. Among authors: neilsen pm. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. Epub 2012 Jun 26. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22736789 Review.

8

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Chee JL, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, Phua YT, Gabra H, Lim TM. Chee JL, et al. Among authors: neilsen pm. Cell Cycle. 2013 Jan 15;12(2):278-88. doi: 10.4161/cc.23054. Epub 2012 Jan 15. Cell Cycle. 2013. PMID: 23255126 Free PMC article.

9

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.

Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Neilsen PM, et al. Oncotarget. 2011 Dec;2(12):1203-17. doi: 10.18632/oncotarget.382. Oncotarget. 2011. PMID: 22203497 Free PMC article.

10

Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.

Noll JE, Jeffery J, Al-Ejeh F, Kumar R, Khanna KK, Callen DF, Neilsen PM. Noll JE, et al. Among authors: neilsen pm. Oncogene. 2012 Jun 7;31(23):2836-48. doi: 10.1038/onc.2011.456. Epub 2011 Oct 10. Oncogene. 2012. PMID: 21986947

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters